123 related articles for article (PubMed ID: 38061174)
41. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
42. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
43. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
44. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
45. [Evaluation of cisplatin ototoxicity by the audiometric curve in retinoblastoma].
Toral-Martinñon R; Collado-Corona MA; Mora-Magaña I; Leal-Leal C; Gutiérrez-Castrellón P; González-de Leo S
Cir Cir; 2006; 74(2):79-82. PubMed ID: 16887078
[TBL] [Abstract][Full Text] [Related]
46. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
47. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
48. Long term hearing degeneration after platinum-based chemotherapy in childhood.
Einarsson EJ; Petersen H; Wiebe T; Fransson PA; Grenner J; Magnusson M; Moëll C
Int J Audiol; 2010 Oct; 49(10):765-71. PubMed ID: 20874050
[TBL] [Abstract][Full Text] [Related]
49. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
50. Variants in
Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
[No Abstract] [Full Text] [Related]
51. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Clemens E; Brooks B; de Vries ACH; van Grotel M; van den Heuvel-Eibrink MM; Carleton B
PLoS One; 2019; 14(2):e0210646. PubMed ID: 30763334
[TBL] [Abstract][Full Text] [Related]
52. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
53. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
54. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
55. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss.
Singh Chauhan R; Saxena RK; Varshey S
Ear Nose Throat J; 2011 May; 90(5):218-22. PubMed ID: 21563089
[TBL] [Abstract][Full Text] [Related]
56. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.
Dille MF; McMillan GP; Helt WJ; Konrad-Martin D; Jacobs P
J Am Acad Audiol; 2015 Oct; 26(9):750-60. PubMed ID: 26415968
[TBL] [Abstract][Full Text] [Related]
57. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
58. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
[TBL] [Abstract][Full Text] [Related]
59. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
Meijer AJM; Li KH; Brooks B; Clemens E; Ross CJ; Rassekh SR; Hoetink AE; van Grotel M; van den Heuvel-Eibrink MM; Carleton BC
Cancer; 2022 Jan; 128(1):169-179. PubMed ID: 34490624
[TBL] [Abstract][Full Text] [Related]
60. High frequency audiometric study in cancer-cured patients treated with cisplatin.
Crepaldi de Almeida EO; Umeoka WG; Viera RC; de Moraes IF
Braz J Otorhinolaryngol; 2008; 74(3):382-90. PubMed ID: 18661012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
